Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
Christian P. Larsen(Emory Healthcare), Robert Peach(Bristol-Myers Squibb (United States)), Dan Anderson(Emory University), JoAnne L. Greene(Bristol-Myers Squibb (United States)), Shannon Cowan(Emory University), Thomas C. Pearson(Emory University), Jürgen Bajorath(University of Bonn), John Emswiler(Bristol-Myers Squibb (United States)), Peter S. Linsley(Bristol-Myers Squibb (Germany)), Joseph Naemura(Bristol-Myers Squibb (United States)), Andrew Adams(Emory University), David Hagerty(Bristol-Myers Squibb (United States)), Paul L. Tso(Emory University), Elizabeth Strobertb(Emory University), Robert Townsend(Bristol-Myers Squibb (United States)), Nozomu Shirasugi(Emory University), Karen Price(Bristol-Myers Squibb (United States)), Lori A. Turk(Bristol-Myers Squibb (United States))
Cited by 708
Related Papers
Docking and scoring in virtual screening for drug discovery: methods and applications
|Nature Reviews Drug Discovery|2004|4k
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Polypharmacology: Challenges and Opportunities in Drug Discovery
|Journal of Medicinal Chemistry|2014|1.1k
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
|Immunity|1994|971
Integration of virtual and high-throughput screening
|Nature Reviews Drug Discovery|2002|940